The effects of bufadienolides on HER2 overexpressing breast cancer cells
Abstract
HER2 is a proto-oncogene frequently amplified in human breast cancer, its overexpression is correlated with tamoxifen resistance and decreased recurrence-free survival. Arenobufagin and bufalin are homogeneous bufadienolides of cardiac glycosides agents. In this research, we studied the effects of arenobufagin and bufalin on cellular survival and proliferation of HER2 overexpressing breast cancer cells and the mechanism under the results including the direct effect on HER2 downstream pathways. Our results showed that arenobufagin and bufalin could significantly inhibit the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-1, SRC-3, nuclear transcription factor E2F1, phosphorylated AKT, and ERK. And the combination of each bufadienolide in low dose with tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpressing breast cancer cells. All above suggest that arenobufagin and bufalin may be potential therapy adjuvants for HER2 overexpressing breast cancer therapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Bufalin has been shown to downregulate expression of transcriptional coactivators SRC-1 and SRC-3, as well as nuclear transcription factor E2F1.
“Furthermore, Bufalin has been shown to downregulate the expression of transcriptional coactivators SRC-1 and SRC-3, as well as the nuclear transcription factor E2F18,43.”
From Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha (2025) · cites this paper as [43]
Cited by
Sorted by citations
Jiang, S., Liu, K., Jiang, T., Li, H., Wei, X., Wan, X., Zhong, C., Gong, R., Chen, Z., Zou, C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62288-7 · Cited by 23 · see citing works
- Authors
- Wang, T., Mu, L., Jin, H., Zhang, P., Wang, Y., Ma, X., Pan, J., Miao, J., & Yuan, Y.
- Affiliations
- Dalian Medical University (CN)
- Corresponding author
- Pan, Jinjin
- Miao, Jian
- Yuan, Yuhui
- ORCID
- Venue
- Tumor Biology
- Published
- 2015-12-12
- Volume
- 37
- Issue
- 6
- Pages
- 7155-7163
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2193036745
- Cited by
- 15
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 2 · 2021: 2 · 2020: 3 · 2018: 1 · 2016: 2
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Tumor Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Liaoning Province
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Physical Sciences › Materials Science › Biomaterials › Phytochemistry and Bioactive Compounds
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Natural product bioactivities and synthesis
- Keywords
- bufadienolides, arenobufagin, bufalin, HER2 overexpression, breast cancer, tamoxifen resistance, combination therapy, cell proliferation, cell survival, Src family kinases, E2F1, Akt phosphorylation, ERK1/2 phosphorylation, cardiac glycosides, therapeutic adjuvant
- MeSH terms
- Proto-Oncogene Mas, Breast Neoplasms, Bufanolides, Cell Cycle, Female, Humans, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
